Selexipag for the Treatment of Pulmonary Arterial Hypertension

Olivier Sitbon, Richard N. Channick, Kelly M Chin, Aline Frey, Sean P. Gaine, Nazzareno Galiè, Hossein-Ardeschir Ghofrani, Marius M. Hoeper, Irene M. Lang, Ralph Preiss, Lewis J. Rubin, Lilla Di Scala, Victor F. Tapson, Igor Adzerikho, Jinming Liu, Olga Moiseeva, Xiaofeng Zeng, Gérald Simonneau, Vallerie V. McLaughlin, GRIPHON Investigators

Research output: Contribution to journalArticlepeer-review


BACKGROUND: In a phase 2 trial, selexipag, an oral selective IP prostacyclin-receptor agonist, was shown to be beneficial in the treatment of pulmonary arterial hypertension.

METHODS: In this event-driven, phase 3, randomized, double-blind, placebo-controlled trial, we randomly assigned 1156 patients with pulmonary arterial hypertension to receive placebo or selexipag in individualized doses (maximum dose, 1600 μg twice daily). Patients were eligible for enrollment if they were not receiving treatment for pulmonary arterial hypertension or if they were receiving a stable dose of an endothelin-receptor antagonist, a phosphodiesterase type 5 inhibitor, or both. The primary end point was a composite of death from any cause or a complication related to pulmonary arterial hypertension up to the end of the treatment period (defined for each patient as 7 days after the date of the last intake of selexipag or placebo).

RESULTS: A primary end-point event occurred in 397 patients--41.6% of those in the placebo group and 27.0% of those in the selexipag group (hazard ratio in the selexipag group as compared with the placebo group, 0.60; 99% confidence interval, 0.46 to 0.78; P<0.001). Disease progression and hospitalization accounted for 81.9% of the events. The effect of selexipag with respect to the primary end point was similar in the subgroup of patients who were not receiving treatment for the disease at baseline and in the subgroup of patients who were already receiving treatment at baseline (including those who were receiving a combination of two therapies). By the end of the study, 105 patients in the placebo group and 100 patients in the selexipag group had died from any cause. Overall, 7.1% of patients in the placebo group and 14.3% of patients in the selexipag group discontinued their assigned regimen prematurely because of adverse events. The most common adverse events in the selexipag group were consistent with the known side effects of prostacyclin, including headache, diarrhea, nausea, and jaw pain.

CONCLUSIONS: Among patients with pulmonary arterial hypertension, the risk of the primary composite end point of death or a complication related to pulmonary arterial hypertension was significantly lower with selexipag than with placebo. There was no significant difference in mortality between the two study groups. (Funded by Actelion Pharmaceuticals; GRIPHON number, NCT01106014.).

Original languageEnglish
Pages (from-to)2522-33
Number of pages12
JournalNew England Journal of Medicine
Issue number26
Publication statusPublished - Dec 24 2015
Externally publishedYes


  • Acetamides
  • Aged
  • Disease Progression
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Hospitalization
  • Humans
  • Hypertension, Pulmonary
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Prodrugs
  • Pyrazines
  • Clinical Trial, Phase III
  • Journal Article
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

Fingerprint Dive into the research topics of 'Selexipag for the Treatment of Pulmonary Arterial Hypertension'. Together they form a unique fingerprint.

Cite this